このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Hormones, Outcomes, and Pain Pathways in Exercise Study (HOPE)

2026年5月28日 更新者:Stacey Gorniak、University of Houston

Mechanical and Non-mechanical Contributions to Chronic Neck, Shoulder, Arm, and Back Pain in Full-busted Women

The goal of the proposed project is to evaluate a mechanical intervention (sports bras designed specifically for full busted women) to alleviate neck, shoulder, arm, and back pain in full-busted women and investigate the contribution of non-mechanical pathways associated with this type of pain in women. Specifically, the investigators will investigate how sex-hormones, inflammation, and remapping of specific regions of the brain contribute to the manifestation of neck, shoulder, arm, and back pain in full-busted women across the lifespan.

調査の概要

詳細な説明

Approximately 130 million individuals in the US (39% of the US population) are living with chronic musculoskeletal pain. Women experience more localizations of pain across their lifespan. Women report significantly more pain in the neck, shoulders, arms, back, and breasts due to altered musculoskeletal activity within in the neck and thoracic region due to the presence of breast tissue. Neck, shoulder, arm, and back (NSAB) pain has been strongly linked to bra cup size. Since 2000, there has been a significant increase in women's average bra cup size from B to E; women with cup sizes D and above are considered "full-busted". Most commercially available sport bras are designed for low- to medium-impact activities for women with cup size C or smaller, leaving women with cup sizes of D or larger without adequate breast support during physical activity. While the primary source of NSAB pain in these women is likely mechanical, evidence suggests non-mechanical pain pathways that may contribute to pain expression in women. Specifically, evidence of sex-hormone influences, systemic inflammation, and cortical remapping in female animal models with respect to chronic musculoskeletal pain is emerging; however, characterization of the influences of sex-hormone levels, inflammation, and concurrent cortical changes in the somatosensory and motor regions particularly in reference to chronic NSAB pain in women across the lifespan is a major gap in the evidence base. This critical gap in understanding physiological and neurological sex differences in chronic NSAB pain manifestation in full-busted women will be filled by our proposed project. In this project, the investigators will evaluate a non-pharmacological (mechanical) intervention to alleviate NSAB pain in full-busted women and investigate non-mechanical pathways associated with chronic NSAB pain in women. The investigators will measure both self-reported and objective measures of pain in conjunction with objective measures of behavior and blood-based measures to assess: (1) the impact of the mechanical intervention and (2) non-mechanical factors contributing to chronic musculoskeletal pain in women. The findings from this project will advance multifactorial understanding of pain in full-busted women, a population that lives with chronic musculoskeletal pain.

研究の種類

介入

入学 (推定)

140

段階

  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Stacey L Gorniak, PhD
  • 電話番号:713-743-4802
  • メール:sgorniak@uh.edu

研究場所

    • Texas
      • Houston、Texas、アメリカ、77204
        • 募集
        • University of Houston
        • コンタクト:
          • Stacey L Gorniak, PhD
          • 電話番号:713-743-4802
          • メール:sgorniak@uh.edu
        • 主任研究者:
          • Stacey L Gorniak, PhD

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人

健康ボランティアの受け入れ

はい

説明

Inclusion Criteria:

  1. Able to provide informed consent
  2. Age of 18 to 60 years
  3. Assigned female sex at birth
  4. Right-handed by self-declaration
  5. Willing to participate in one online testing session and up to four in-person testing sessions
  6. Bra band size between 32-40"
  7. International Physical Activity Questionnaire - Short Form (IPAQ-SF) score of 2 or higher
  8. An answer of "NO" to any item of the general health questions of the PARQ+
  9. No history of surgery to the: back, neck, or shoulders or joint replacement
  10. No history of implanted pacemakers or other stimulation devices
  11. No history of spinal cord injury (SCI)

Exclusion Criteria:

  1. Inability to provide informed consent
  2. Age 17 years old or younger or 61 years or older
  3. Assigned male sex at birth
  4. Left-handed by self-declaration
  5. Not willing to participate in one online testing session and up to four in-person testing sessions
  6. Bra band size greater than 40" or less than 32"
  7. IPAQ-SF score of 1 or lower
  8. An answer of "YES" to any item of the general health questions of the PARQ+
  9. History of limb amputation (upper or lower extremity)
  10. Presence of open pressure sores on the upper or lower extremities
  11. Currently pregnant or lactating/breastfeeding
  12. History of surgery to the: back, neck, or shoulders or joint replacement
  13. History of breast cancer and/or mastectomy
  14. History of implanted pacemakers or other stimulation devices
  15. History of spinal cord injury (SCI)
  16. History of joint disease including osteoarthritis and/or Rheumatoid Arthritis
  17. History of the following neurological diseases: Cerebrovascular accident (CVA, stroke), Alzheimer's Disease (AD), Dementia (of any form), Huntington's Disease, Traumatic Brain Injury (TBI), Spinal cord injury (SCI), Multiple Sclerosis (MS), Parkinson's Disease (PD), Polio, Paraproteinaemic Demyelinating Neuropathy (PDN) and/or Monoclonal Gammopathy of Undetermined Significance (MGUS), Myasthenia Gravis, Muscular Dystrophy, Guillain-Barré Syndrome, Scoliosis, Charcot-Marie-Tooth Disorder or other hereditary neuropathies

Additional Inclusion Criteria for Intervention Group:

a. Self-declared breast size of D-I cup (US sizes: D, E, F, G, H)

Additional Inclusion Criteria for the Control Group:

a. Self-declared breast size of A-C cup (US sizes: AA, A, B, C)

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:基礎科学
  • 割り当て:非ランダム化
  • 介入モデル:並列代入
  • マスキング:ダブル

武器と介入

参加者グループ / アーム
介入・治療
介入なし:Control
Women with bra cup sizes A - C. Control group will undergo measurement of kinematic and kinetic data during physical activities at baseline. Study questionnaires, pain measures, body composition, brain activity, and blood-based biomarkers will be collected at baseline. Physical activity will be tracked via smartwatch for 3 months after baseline.
実験的:Interventional Sports Bra
Women with bra cup sizes D - I. Intervention group will undergo measurement of kinematic and kinetic data during physical activities at baseline and 3 months after receiving their interventional sports bras. Study questionnaires, pain measures, body composition, brain activity, and blood-based biomarkers will be collected at baseline and 3 months after receiving the interventional sports bras. Physical activity will be tracked via smartwatch for 3 months after baseline.
This study involves use of observation and analysis of behavior in assessing breast motion and associated health outcomes while using a provided interventional sports bra of participant choice (Bounceless bra or Shefit Ultimate bra) for 3 months.
他の名前:
  • Bounceless bra
  • Shefit Ultimate bra

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Pain Measures
時間枠:Baseline and 3 months after baseline
Qualitative assessment of pain via self-report (no units)
Baseline and 3 months after baseline
Objective Pain Measure
時間枠:Baseline and 3 months after baseline
Nociceptive Flexion Reflex Threshold (mV)
Baseline and 3 months after baseline
Physical activity
時間枠:Baseline and 3 months after baseline
Frequency and duration of physical activity as measured via smartwatch
Baseline and 3 months after baseline
Anthropometry
時間枠:Baseline and 3 months after baseline
Percent body fat (%)
Baseline and 3 months after baseline
Anthropometry
時間枠:Baseline and 3 months after baseline
Body mass index (BMI) (kg/m²)
Baseline and 3 months after baseline
Glycated Hemoglobin
時間枠:Baseline and 3 months after baseline
A1c (%)
Baseline and 3 months after baseline
Lipids
時間枠:Baseline and 3 months after baseline
Total Cholesterol (mg/dL)
Baseline and 3 months after baseline
Lipids
時間枠:Baseline and 3 months after baseline
High Density Lipoprotein Cholesterol (HDL) (mg/dL)
Baseline and 3 months after baseline
Biomechanical Data
時間枠:Baseline and 3 months after baseline
Muscle activity (mV)
Baseline and 3 months after baseline
Neuroimaging Data
時間枠:Baseline and 3 months after baseline
Oxygenated Hemoglobin (HbO) (p-value)
Baseline and 3 months after baseline
Neuroimaging Data
時間枠:Baseline and 3 months after baseline
Deoxygenated Hemoglobin (HbR) (p-value)
Baseline and 3 months after baseline

二次結果の測定

結果測定
メジャーの説明
時間枠
Blood Pressure
時間枠:Baseline and 3 months after baseline
Systole and Diastole (mmHg)
Baseline and 3 months after baseline
Systemic Inflammation Index
時間枠:Baseline and 3 months after baseline
SII (no units)
Baseline and 3 months after baseline
Neuroimaging Data
時間枠:Baseline and 3 months after baseline
Total Hemoglobin (HbT) (p-value)
Baseline and 3 months after baseline
Biomechanical Data
時間枠:Baseline and 3 months after baseline
Breast tissue acceleration (m/s2)
Baseline and 3 months after baseline
Biomechanical Data
時間枠:Baseline and 3 months after baseline
Gait speed (m/s)
Baseline and 3 months after baseline
Biomechanical Data
時間枠:Baseline and 3 months after baseline
Cadence (Hz)
Baseline and 3 months after baseline
Menopausal Status
時間枠:Baseline
Age at menopause (years) - if applicable
Baseline
Sex-Hormones
時間枠:Baseline and 3 months after baseline
Testosterone (mg/dL)
Baseline and 3 months after baseline
Sex-Hormones
時間枠:Baseline and 3 months after baseline
Estradiol (mg/dL)
Baseline and 3 months after baseline
Sex-Hormones
時間枠:Baseline and 3 months after baseline
Progesterone (mg/dL)
Baseline and 3 months after baseline
Sex-Hormones
時間枠:Baseline and 3 months after baseline
Follicle Stimulating Hormone (mg/dL)
Baseline and 3 months after baseline
Sex-Hormones
時間枠:Baseline and 3 months after baseline
Sex Hormone Binding Globulin (nmol/L)
Baseline and 3 months after baseline

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Stacey L Gorniak, PhD、University of Houston

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年5月17日

一次修了 (推定)

2029年6月1日

研究の完了 (推定)

2029年9月1日

試験登録日

最初に提出

2026年5月4日

QC基準を満たした最初の提出物

2026年5月4日

最初の投稿 (実際)

2026年5月12日

学習記録の更新

投稿された最後の更新 (実際)

2026年6月2日

QC基準を満たした最後の更新が送信されました

2026年5月28日

最終確認日

2026年5月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

What data outputs will the research generate?

Biomechanical Evaluation Data Blood-based Biomarker Data (e.g., inflammation markers, sex-hormone values) Health State Data (e.g., blood pressure values, BMI, body composition values, menopausal status) Pain Data Physical Activity Data Functional Neuroimaging Data (t-values of Cortical Oxygenated, Deoxygenated, and Total Hemoglobin)

Manuscripts (which will also be publicly available via Pubmed upon publication)

IPD 共有時間枠

Data will be available as soon as possible but no later than within one year of the completion of the funded project period or upon acceptance of specific data for publication. Data will be available for 5 years after the completion of the funded project.

IPD 共有アクセス基準

Deidentified data will be made available to the research community via Zenodo. Potential data users must agree to: (1) credit the original study, study team, and investigators; (2) protect study participants by limiting data use to scientific research and aggregate statistical reporting; (3) will not attempt to identify and/or contact study participants, and (4) will agree not to share or redistribute any data downloads.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する